Table 2.
Drug-related adverse events
| N = 26 | Any grade | Grade 3 |
|---|---|---|
| Injection site reaction | 26 | 0 |
| Hypertension | 8 | 5 |
| Malaise | 3 | 0 |
| Sinus tachycardia | 3 | 0 |
| LDH increased | 3 | 0 |
| Hyperkalemia | 3 | 0 |
| Hypertriglyceridemia | 3 | 0 |
| Chills | 2 | 0 |
| QTc interval prolongation | 2 | 0 |
| Platelet count decreased | 2 | 0 |
| ALT increased | 2 | 0 |
| Fibrinogen increased | 2 | 0 |
| FDP increased | 2 | 0 |
| Anorexia | 1 | 1 |
Grade 1 anemia, increased ALP, decreased APTT, increased CPK, dysgeusia, hypokalemia, hyponatremia, infection (herpes zoster virus), decreased lymphocyte count and sore throat were observed in 1 patient each. No grade 4–5 drug-related AEs were observed
ALT alanine aminotransferase, FDP fibrin degradation products, LDH lactate dehydrogenase